Multi-Modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma
This Liquid Biopsy Research Laboratory (LBRL) will address specific unmet clinical needs in the early assessment of cancer by developing and validating multi-analyte liquid biopsy (LBx) technologies. As a partnership with Liquid Biopsy for Early-Cancer Assessment Consortium (LBC) and National Cancer Institute (NCI), we will accomplish this by bringing together clinical, research, and industry experts capable of advancing LBx projects in distinct clinical contexts to maximize patient benefit. The LBRL will actively pursue interactions to leverage resources and expertise for the greatest progress in the shortest possible time.
Research projects will address current clinical gaps in the early assessment of cancer using LBx technologies that could offer substantial clinical benefits in distinct populations. Three projects will be staged to maximally leverage resources toward gaining sufficient evidence for clinical implementation of at least one project by the end of the initial period. The specific projects proposed here are focused on refining and validating technologies, methods, and assays for LBx for early assessment of cancers with a particular emphasis on integrating the genomics and proteomics of single cells, along with plasma genomics and proteomics to configure a final, clinically impactful assay. The LBRL has demonstrated capabilities in the LBx of peripheral blood (PB), cerebral spinal fluid (CSF), bone marrow aspirate (BMA), aqueous humor (AH), and ascites. Clinical utilities will be explored in both screening and diagnostic workup in the early assessment of cancer with the LBx.
Learn more: NIH/NCI Liquid Biopsy Consortium
